Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07153952

RT for Adenocarcinoma/Adenosquamous Carcinoma

This study aims to establish a prospective cohort of locally advanced cervical adenocarcinoma to provide a better way to monitor its efficacy and provide precise treatment. The key problems to be solved are as follows:

1. Establish an observational prospective cohort of locally advanced ADC and randomly divide patients with residual cervical tumors in the primary site after CCRT into the local treatment group (salvage surgery or supplementary radiotherapy) or the systemic treatment group. 2. Collect cervical biopsy tissues before and after CCRT in patients with residual cervical tumors, explore the genomic characteristics, and predict whether they can benefit from targeted/immunotherapy in the future.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Radiotherapy

Age range

18 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathological diagnosis of cervical adenocarcinoma;
  • Age 18-80 years old;
  • FIGO 2018 stage IB3-IVA;
  • Karnofsky score≥60 points;
  • Complete blood count, and comprehensive metabolic panel meet the conditions for CCRT;
  • No metal implants in the body, and can perform MRI examination;
  • Willing to participate in this study and provide written informed consent.

Exclusion criteria

  • Patients who have received pelvic radiotherapy before;
  • Patients whose target tumors have been treated before (chemotherapy, immunotherapy, surgical treatment, etc.);
  • Allergy to iodine contrast agent;
  • Participating in other clinical studies that may affect the results of this study (determined by the principal investigator);

f) Serious diseases that may significantly affect compliance with clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment; g) Other situations that the investigator believes are not suitable for participation in this clinical study.

Treatment and study plan

Radiotherapy

Radiation

The surgical method is determined by the gynecological oncologist, including total hysterectomy, pelvic exenteration, or radical total hysterectomy. The specific surgical choice needs to be comprehensively judged based on the patient's residual tumor location, size, and other complications. Supplementary radiotherapy is mainly image-guided brachytherapy ± external irradiation. The irradiation range and dose must be comprehensively considered based on the location and size of the residual lesions. The best local treatment plan is jointly determined by gynecological oncologists and radiotherapists.

Systemic treatment

Drug

Systemic treatment regimens include chemotherapy ± targeted therapy ± immunotherapy. According to the NCCN Guidelines (2024.V2), the first-line chemotherapy regimen for persistent, recurrent, or metastatic cervical cancer is preferably carboplatin/paclitaxel and cisplatin/paclitaxel. The addition of immunotherapy can be determined based on the PD-L1 expression level. The specific chemotherapy regimen will be determined by the gynecological oncologist based on the residual tumor site, the number of lesions, and other complications. In addition, if the patient's pathological results indicate HER2 positivity or the genetic test results show PIK3CA mutation, targeted therapy, such as neratinib or apelisimab, can be considered as a second-line regimen after the first-line chemotherapy regimen progresses.

Primary outcomes

  1. Tumor control rate

    Time frame: Tumor control rate among patients with residual cervical tumors in the two groups 3 months after treatment

Secondary outcomes

  1. progression-free survival

    Time frame: 2-year progression-free survival

    The time from randomization to the occurrence of disease recurrence or death from any cause within 2 years was determined based on the time of the first event. If no such event occurred, the time was determined to the last follow-up.

  2. overall survival

    Time frame: 2-year overall survival rate

    The time interval from randomization to death from any cause within 2 years, or if there was no death, to the last follow-up time

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Collaborators

  • Heilongjiang Provicial Hospital
  • Liaoning Cancer Hospital & Institute
  • Luohe Central Hospital
  • Obstetrics and Gynecology Hospital of Zhejiang University
  • The First Affiliated Hospital of Xiamen University

Registry information

Official study title

Evaluation of the Treatment Response and Prognosis of Cervical Adenocarcinoma/Adenosquamous Carcinoma After Radiotherapy Based on Pathologic Characteristics and Multimodal Imaging: a Prospective, Multicenter Trial

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Sep 4, 2025
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.